{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Colocynthin is the active medicinal principle of colocynth; a bitter, yellow, crystalline substance, regarded as a glucoside. Colocynthin is cytotoxic with respect to HeLa cells.
Status:
US Previously Marketed
Source:
LIVOSTIN by NOVARTIS
(1993)
Source URL:
First approved in 1993
Source:
LIVOSTIN by NOVARTIS
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Levocabastine (trade name Livo) is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis. Levocabastine binds the G protein-coupled neurotensin receptor 2 (NTR2), but not NTR1, where it behaves as a weak partial inverse agonist. In an environmental study, LIVOSTIN 0.05% (levocabastine hydrochloride ophthalmic suspension) instilled four times daily was shown to be significantly more effective than its vehicle in reducing ocular itching associated with seasonal allergic conjunctivitis. After instillation in the eye, levocabastine is systemically absorbed. However, the amount of systemically absorbed levocabastine after therapeutic ocular doses is low (mean plasma concentrations in the range of 1-2 ng/mL). Brand name Livostin is no longer available in the U.S., but generic versions may still be available. Common side effects include burning, stinging, itching, or watering of the eyes, eye irritation or discomfort, blurred vision, dry or puffy eyes, headache, nosebleed, nausea, or fatigue.
Status:
First approved in 1956
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
METHITURAL (as sodium salt) is a barbiturate derivative which was used as an ultrashort-acting intravenous anesthetic.
Status:
US Previously Marketed
Source:
PROMIN by PD
(1961)
Source URL:
First approved in 1945
Class (Stereo):
CHEMICAL (MIXED)
Glucosulfone (Glucosulfone Free Acid, or Promin) is a compound used to treat mycobacterial infections, such as tuberculosis and leprosy. It is converted to dapsone in the body, which also has been shown to have therapeutic effects against dermatitis herpetiformis, actinomycotic mycetoma, asthma, malaria, rheumatoid arthritis, Kaposiís sarcoma, pneumocystis carinii (pneumonia), subcorneal pustular dermatosis and cystic acne. Once converted to dapsone, it has haemotoxic effects (destroying red blood cells, or disrupting blood clotting, potentially causing organ or tissue damage).
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ABSOLUTE)
Penimepicycline is a salt of beta-lactam antibiotic penicillin V and tetracycline antibiotic pipacycline. Penimepicycline exerts a bactericidal action on the streptococci, and a bacteriostatic action on various gram-positive and gram-negative bacilli, as well as on the penicillin-resistant staphylococci. In the 1960s it was studied in Japan for the treatment of urological, respiratory, gynecological and other infections.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Eseridine (Geneserine) has been known for many years as an anticholinergic agent and used in therapy as a gastrointestinal antispastic. Eseridine salicylate is an inhibitor of cholinesterase activity that has been given by mouth in preparations for dyspepsia and other gastric disorders. It has also been studied for the treatment of Alzheimer’s disease.